Targeting CD26hi T-cells for Cancer Therapy
Inventors at MUSC have identified a unique human CD4+ T cell population that expresses high levels of surface CD26, termed CD26high T cells, which mediate durable antitumor immunity in vivo, and have immediate clinical relevance for designing new vaccines and cellular therapies.
CD26high T cells simultaneously secrete elevated IL-17A, IFN-? and IL-22 compared to Th1, Th2 or Th17 cells. When infused into mice bearing human tumors, CD26high T cells more efficiently reconstituted immunodeficient hosts and persisted long-term compared to other subsets. Remarkably, CD26high T cells engineered with a first generation CD3? mesothelin-specific chimeric antigen receptor (CAR) were capable of ablating large human mesothelioma tumors when infused into mice.
Spinal Implant System for Reduction & Internal Implant Stabilization of Human Spondylolisthesis Deformity
The Hercules spinal implant device and system is to be used for reduction and internal implant stabilization of human vertebral spondylolisthesis deformity. It is a standalone system with unique design that allows an anterior surgical approach to realign and simultaneously stabilize the spinal vertebral segments while protecting and preserve nerve function and not damaging other human body visceral anatomy in order to correct all grades of spondylolisthesis. The proposed solution is to use two implants in the interbody space, allowing greater flexibility to handle high grades of spondylolisthesis that utilize a locking mechanism when the spine has returned to proper alignment to provide the same stability as that of a single implant. Additionally, the reduction system used to realign the spine is designed to minimize the physical strain of the surgeon while realigning the spine, which could have high resistive forces in high grades of spondylolisthesis. This spinal reduction system is able to treat any grade of spondylolisthesis without supplemental fixation. This is used to treat patients with the spondylolisthesis deformity that causes extreme back or leg pain, and who have found no improvement with more conservative treatment options.
Titanium Clip Metal Detector to Aid Breast Surgery
This titanium metal detector localizes titanium biopsy clips placed at the site of breast tissue biopsies. The device is a handheld metal detector that can be inserted into a surgical incision to help locate small titanium markers without an invasive procedure to insert a localizing wire or radioactive seed. The device uses a two-step detection system which is initiated by running the scanning wand across the patient’s breast as a means of rapidly guiding clinicians to the marker’s general location. Once an approximate location is determined, the probing wand is used to identify the marker’s precise location. An incision is made and the probing wand guides the surgeon’s path to the marker through continuous feedback. The system relates proximity information to clinicians both through auditory feedback mechanisms and a digital display on the base.
Cooperative Therapeutic Effect of Immune Checkpoint Blockade & Anti-sMIC
The invention is a new immune-based therapy modality to treat MIC+ malignancies by the combination of a sMIC neutralizing antibody and an immune checkpoint agonist. This invention presents that a combination of sMIC antibody and anti-CTLA4 or anti-PD1/PD-L1 has superior therapeutic effect over monotherapy of individual reagents. This is a new therapeutic modality to improve the clinic response to anti-CTLA4 or anti-PD1/PD-L1 therapy.
Zeriscope Mobile Telemedicine System Receives U.S. Patent
Cloud-based platform allows physicians to examine patients wherever they are
CHARLESTON, S.C. (Dec 1. 2017) – Key components of Zeriscope, a comprehensive mobile telemedicine examination system, received a United States patent Nov. 14.
Robert J. Adams, M.D., developed the concepts behind Zeriscope as part of his work at the Medical University of South Carolina (MUSC). He received assistance in securing Zeriscope’s patent from the MUSC Foundation for Research Development (FRD). The company also received financial assistance from the South Carolina Research Authority (SCRA) SC Launch program and the South Carolina Smart State Centers of Excellence program.
Sachs Wins MUSC FRD's 2017 Innovation Award
Barton Sachs, M.D., professor of orthopaedics, is the winner of the 2017 Admiral Albert J. Baccioco Innovator of the Year Award, the highest honor awarded by the Medical University of South Carolina’s Foundation for Research Development (FRD). The award recognizes MUSC researchers and clinicians who are working to promote commercialization of university intellectual property through new inventions, patents applied for, technologies licensed, and new startups formed.
“I appreciate this recognition,” Sachs said. “The annual award is a representation of how the combination of energy, institutional support, team commitment, and social culture can advance innovation and entrepreneurship. I extend my gratitude to FRD and MUSC for the promotion of new ideas and avant-guard solutions to current problems.”
MUSC Foundation for Research Development Announces Two New Board Members
Charleston, S.C. (May 25, 2017)
– MUSC Foundation for Research Development (FRD) has announced the appointment of two new members to its board of directors, as well as the full slate of directors for 2017-2018.
Joining the board are William (Bill) Himmelsbach, MPH, FACHE and Julia (Julie) Barnes-Weise, JD, CLP. "Julie and Bill are highly accomplished health care executives with relevant experience and accomplishments to guide FRD as we continue to bring forward technologies in support of the MUSC mission to help patients,” said Arlene Morris, newly-elected chair of the FRD board. “We look forward to their insights and contributions in support of the FRD mission, and welcome Bill and Julie to the board.”